{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:25:13Z","timestamp":1789878313489,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.lungcan.2017.08.021","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T16:49:19Z","timestamp":1504284559000},"page":"37-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"special_numbering":"C","title":["EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study"],"prefix":"10.1016","volume":"113","author":[{"given":"Baohui","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Tjulandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laksmi","family":"Wulandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Laktionov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achmad","family":"Hudoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.08.021_bib0005","series-title":"Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012","author":"World Health Organization. GLOBOCAN","year":"2012"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0010","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ejca.2012.03.007","article-title":"Lung cancer in never smokers\u2013a review","volume":"48","author":"Couraud","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0015","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0020","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jtho.2016.05.036","article-title":"ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study","volume":"11","author":"Reck","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000302729","article-title":"High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma","volume":"33","author":"Moiseyenko","year":"2010","journal-title":"Onkologie"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0030","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1158\/0008-5472.CAN-06-4229","article-title":"Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history","volume":"67","author":"Mounawar","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0035","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/annonc\/mdm003","article-title":"Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib","volume":"18","author":"Hirsch","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0040","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.2005.07.799","article-title":"Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions","volume":"23","author":"Pao","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0045","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1158\/1078-0432.CCR-06-0658","article-title":"Update on epidermal growth factor receptor mutations in non-small cell lung cancer","volume":"12","author":"Riely","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0050","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/JTO.0000000000000263","article-title":"Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status","volume":"9","author":"Douillard","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0060","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2016.11.022","article-title":"Efficacy according to blind independent central review: post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin\/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC","volume":"104","author":"Wu","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0075","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0080","unstructured":"NICE. EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. http:\/\/www.nice.org.uk\/guidance\/dg9. (Accessed 20 March, 2017)."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0085","series-title":"Lung Cancer: Diagnosis and Management","author":"National Collaborating Centre for Cancer (UK)","year":"2017"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0090","series-title":"Practice Guidelines in Oncology \u2013 Version V.4. (non-small-cell Lung Cancer)","author":"National Comprehensive Cancer Network","year":"2017"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0095","first-page":"119","article-title":"Recommendations for mutational analysis of EGFR in lung carcinoma","volume":"102","author":"Marchetti","year":"2010","journal-title":"Pathologica"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0100","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/JTO.0b013e3181f1c8de","article-title":"Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop","volume":"5","author":"Pirker","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0105","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0115","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0120","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open label, single arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0130","doi-asserted-by":"crossref","first-page":"e56011","DOI":"10.1371\/journal.pone.0056011","article-title":"EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital","volume":"8","author":"Choi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0135","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4143\/crt.2013.45.3.178","article-title":"How molecular understanding affects to prescribing patterns and clinical outcome of gefitinib in non-small cell lung cancer? 10year experience of single institution","volume":"45","author":"Keam","year":"2013","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0140","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1200\/JCO.2010.31.8923","article-title":"American Society of Clinical Oncology Provisional Clinical Opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy","volume":"29","author":"Keedy","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0145","doi-asserted-by":"crossref","first-page":"12501","DOI":"10.18632\/oncotarget.13915","article-title":"Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer","volume":"8","author":"Normanno","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/JTO.0b013e3182307f98","article-title":"Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS a phase III study of gefitinib or carboplatin\/paclitaxel in non-small cell lung cancer","volume":"7","author":"Goto","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0155","doi-asserted-by":"crossref","first-page":"965","DOI":"10.7314\/APJCP.2016.17.3.965","article-title":"Prevalence and clinical profile of EGFR mutation in non-small-cell lung carcinoma patients in Southwest China","volume":"17","author":"Zhou","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0160","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3892\/ol.2014.2160","article-title":"Investigation of the epidermal growth factor receptor mutation rate in non-small cell lung cancer patients and the analysis of associated risk factors using logistic regression","volume":"8","author":"Pan","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0165","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3892\/mco.2015.564","article-title":"Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China","volume":"3","author":"Abdurahman","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0170","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1185\/03007995.2015.1036015","article-title":"Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung","volume":"31","author":"Tjulandin","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0175","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/cncy.21281","article-title":"Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides","volume":"121","author":"Mitiushkina","year":"2013","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0180","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi Au","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0185","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.lungcan.2015.10.004","article-title":"EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291","volume":"90","author":"Thress","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2017.08.021_bib0190","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2017.08.021_bib0195","first-page":"S204","article-title":"Retrospective analysis of ctDNA EGFR mutations in the Phase III, randomized IMPRESS study","volume":"10","author":"Kim","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0200","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-15-1260","article-title":"Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase 1 study of rociletinib (CO-1686)","volume":"22","author":"Karlovich","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11568-011-9149-2","article-title":"Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours","volume":"4","author":"Aung","year":"2010","journal-title":"Hugo J."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0210","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.08.021_bib0215","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","article-title":"Rociletinib in EGFR-mutated non-small-cell lung cancer","volume":"372","author":"Sequist","year":"2015","journal-title":"N. Engl. J Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217304968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217304968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T18:32:36Z","timestamp":1602873156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217304968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":43,"alternative-id":["S0169500217304968"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.08.021","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}